Equity Research Medical Devices

Should You Buy Anteris Technologies Global Corp. Stock in 2026?

By CirclFi Research Team · · Updated · 1/13 models active

According to the CirclFi Deep Alpha Valuation Engine, Anteris Technologies Global Corp. (AVR) carries a solid Quality of Company rating of 6.1/10. Trading at $7.05, our multi-model framework evaluates whether the company's financial profile offers a favorable risk-reward setup.

The short answer: 0 of 1 CirclFi valuation models project upside for Anteris Technologies Global Corp. (AVR) at $7.05 — the model consensus leans bearish, with a Quality Score of 6.1/10 and Value-Trap risk of 0/100. The full bull case, bear case, and risk factors are below. Educational analysis, not financial advice.

Key Takeaways

  • 1 of 1 models suggest overvaluation — majority bearish
  • Quality Score: 6.1/10 — Moderate — mixed signals
  • Value Trap Risk: 0/100 — Minimal — healthy fundamentals
  • Fair Value Range: $3.29 – $3.29 (0% spread)

Bullish Models

0 / 1

Bearish Models

1 / 1

Quality Score

6.1 /10

Moderate — mixed signals

Value Trap Risk

0 /100
Minimal

Minimal — healthy fundamentals

Model Consensus

1 /13
Active Models

Avg. confidence: 52%

What Is the Investment Case for Anteris Technologies Global Corp. (AVR) in 2026?

What Is the Bull Case vs the Bear Case for Anteris Technologies Global Corp. (AVR)?

Bull case versus bear case for Anteris Technologies Global Corp. (AVR) at $7.05, derived from 1 active CirclFi valuation models on 2026-10-07.
Bull case Bear case — $3.29 target (-53.3%)
No active model projects meaningful upside for AVR at $7.05. Bulls would have to argue that qualitative factors the models cannot measure will unlock value. According to the CirclFi Deep Alpha Valuation Engine, the Dynamic NAV model sees the stock as overvalued with a fair value of $3.29 (-53.3%), suggesting that the market price embeds overly optimistic growth assumptions.
Industry headwind: clinical trial failure represents a meaningful risk for Anteris Technologies Global Corp. and its Medical Devices peers.

How Does AVR Compare to Its Medical Devices Peers?

CBLL CeriBell, Inc.
6.1
ENOV Enovis Corporation
6.1
NSPR InspireMD, Inc.
6.1
BBNX Beta Bionics, Inc.
6.1
OM Outset Medical, Inc.
6.1
NMTC NeuroOne Medical Tec
6.1
VTAK Flyte Aviation, Inc.
5.1
UFPT UFP Technologies, In
9.2

Valuation data pages: CBLL · ENOV · NSPR · BBNX · OM · NMTC · VTAK · UFPT · PHG · IRMD · PODD

See full Medical Devices rankings →

Which Other Stocks Score Like AVR on Quality?

Closest companies to AVR’s Quality of Company score of 6.1/10, across all industries.

Why Do CirclFi’s 1 Models Disagree on AVR?

Spread

0%

Fair Value Range

$3.29 – $3.29

A tight 0% spread suggests meaningful convergence, strengthening conviction in the composite estimate.

Most Bullish

Dynamic NAV

$3.29 (-53.3%)

Most Bearish

Dynamic NAV

$3.29 (-53.3%)

What Are the Biggest Risks of Buying AVR Stock?

Bearish Consensus

1/1 models suggest overvaluation.

Macro/Sector Risk

Medical Devices headwinds could affect earnings trajectory.

Model Limitations

Backward-looking models cannot predict disruptions.

Want the full 13-model breakdown?

See every fair value, confidence score, and value trap analysis.

View AVR Data Page →

So Is Anteris Technologies Global Corp. (AVR) Worth Buying in 2026?

Our valuation engine sends a clear cautionary signal on Anteris Technologies Global Corp. at $7.05. 1/1 models flag overvaluation, median fair value sits at $3.29 (-53.3%), and the risk-reward profile appears unfavorable. Quality at 6.1/10 adds to the concern. This is a stock where patience — or avoidance — may be the optimal strategy.

These are quantitative model outputs, not investment recommendations. Anteris Technologies Global Corp.'s future depends on factors — management execution, competitive dynamics, regulatory changes — that no algorithm can fully capture. See all 13 model estimates →

What Else Do Investors Ask About AVR Stock?

Should I buy AVR stock right now?

Based on CirclFi's multi-model analysis, 0 of 1 models see upside for AVR at $7.05. No active models currently project upside, suggesting the market price may already reflect or exceed fair value. This is not a buy recommendation — see our full disclaimer.

What are the biggest risks of investing in Anteris Technologies Global Corp.?

Key risks include: limited model coverage (1/13 active), reducing analytical confidence; general market and sector-specific risks affecting Medical Devices companies. Always diversify and consult a financial advisor.

How does AVR compare to its competitors?

Among Medical Devices peers, AVR holds a Quality Score of 6.1/10. Comparable companies include CBLL (QOC 6.1), ENOV (QOC 6.1), NSPR (QOC 6.1). The relative ranking helps investors identify whether AVR offers better fundamental quality than alternatives in the same sector.

Is AVR a good long-term investment?

Long-term investment potential depends on fundamental quality and sustainable competitive advantages. AVR's Quality Score of 6.1/10 suggests moderate fundamentals — not a clear long-term hold without further research into growth catalysts. Check our full data page for all 13 model estimates.

What price should I buy AVR at?

CirclFi does not provide target buy prices or price alerts. However, our 1 active models produce fair value estimates ranging from $3.29 to $3.29. At $7.05, the stock trades above all model estimates. Many value investors look for a 20-30% margin of safety below intrinsic value before buying.

Want the complete picture?

See all 13 model estimates, confidence scores, and the full valuation table for AVR.

View AVR Data Page Full Terminal — $60/mo

Disclaimer: This article is produced by the CirclFi Valuation Engine using quantitative models and is for educational and informational purposes only. It is not financial advice, a buy/sell recommendation, or a solicitation to trade securities. Past performance is not indicative of future results. All data sourced from SEC EDGAR, FRED, and GDELT. Consult a licensed financial advisor before making investment decisions. Full disclaimer →